# PeptideScanner evidence objects: Enfuvirtide

Every published version of the records placed with Enfuvirtide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json. Selected public evidence only; not medical advice.

- Objects: 49
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00001118-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00001118

> PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00001118-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00001118-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00001118-enfuvirtide-v1
- Content SHA-256: `5b3e1c7bc8466ba69d311ff423d9175db318b0bc94f29d35578d3e0ea9656e8b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00001118 ([`ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d`](#source-ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d`](#source-ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d`](#source-ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d`](#source-ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d))

### Sources

<a id="source-ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d"></a>
- **ClinicalTrials.gov record NCT00001118 · retained source version 2021-11-01:bb86b5b6db2d9a5ed169098679baadb396f7f61f5553b44258d8e333f3349eee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00001118) (`ctg-observation-nct00001118-2021-11-01-bb86b5b6db2d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00001118." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00001118-enfuvirtide-v1 SHA-256: 5b3e1c7bc8466ba69d311ff423d9175db318b0bc94f29d35578d3e0ea9656e8b.

---

<a id="clinicaltrials-gov-nct00002228-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00002228

> PeptideScanner retained ClinicalTrials.gov record NCT00002228 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00002228-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002228-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00002228-enfuvirtide-v1
- Content SHA-256: `863a0f57c293a634915a00f9bfd88b8af8df438762b6aec630aa9a85d995207b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002228 ([`ctg-observation-nct00002228-2005-06-24-204d41318ce8`](#source-ctg-observation-nct00002228-2005-06-24-204d41318ce8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002228 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00002228-2005-06-24-204d41318ce8`](#source-ctg-observation-nct00002228-2005-06-24-204d41318ce8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002228 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00002228-2005-06-24-204d41318ce8`](#source-ctg-observation-nct00002228-2005-06-24-204d41318ce8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002228-2005-06-24-204d41318ce8`](#source-ctg-observation-nct00002228-2005-06-24-204d41318ce8))

### Sources

<a id="source-ctg-observation-nct00002228-2005-06-24-204d41318ce8"></a>
- **ClinicalTrials.gov record NCT00002228 · retained source version 2005-06-24:204d41318ce8d911d0abb6f811288259ee3dba43f40cab88ee5b33f564e185f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002228) (`ctg-observation-nct00002228-2005-06-24-204d41318ce8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002228." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00002228-enfuvirtide-v1 SHA-256: 863a0f57c293a634915a00f9bfd88b8af8df438762b6aec630aa9a85d995207b.

---

<a id="clinicaltrials-gov-nct00002239-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00002239

> PeptideScanner retained ClinicalTrials.gov record NCT00002239 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-11-15, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00002239-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00002239-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00002239-enfuvirtide-v1
- Content SHA-256: `86d0c8242a8674f6f5ff415c5b4f742112d061eb8869e090340d2201fd9ae374`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00002239 ([`ctg-observation-nct00002239-2005-11-15-a3a647dc25af`](#source-ctg-observation-nct00002239-2005-11-15-a3a647dc25af))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00002239 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-11-15, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00002239-2005-11-15-a3a647dc25af`](#source-ctg-observation-nct00002239-2005-11-15-a3a647dc25af))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00002239 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-11-15, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00002239-2005-11-15-a3a647dc25af`](#source-ctg-observation-nct00002239-2005-11-15-a3a647dc25af))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00002239-2005-11-15-a3a647dc25af`](#source-ctg-observation-nct00002239-2005-11-15-a3a647dc25af))

### Sources

<a id="source-ctg-observation-nct00002239-2005-11-15-a3a647dc25af"></a>
- **ClinicalTrials.gov record NCT00002239 · retained source version 2005-11-15:a3a647dc25af3bcc7cc2657273a800b20a6406ff5c12744223b642472ba0f638** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00002239) (`ctg-observation-nct00002239-2005-11-15-a3a647dc25af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00002239." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00002239-enfuvirtide-v1 SHA-256: 86d0c8242a8674f6f5ff415c5b4f742112d061eb8869e090340d2201fd9ae374.

---

<a id="clinicaltrials-gov-nct00008528-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00008528

> PeptideScanner retained ClinicalTrials.gov record NCT00008528 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00008528-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00008528-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00008528-enfuvirtide-v1
- Content SHA-256: `d1f904f20084f2fb7d2aab22ecdd6ec3de0d220af639a240d1c6b70b33ab79a6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00008528 ([`ctg-observation-nct00008528-2005-06-24-dd6e8c319522`](#source-ctg-observation-nct00008528-2005-06-24-dd6e8c319522))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00008528 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00008528-2005-06-24-dd6e8c319522`](#source-ctg-observation-nct00008528-2005-06-24-dd6e8c319522))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00008528 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00008528-2005-06-24-dd6e8c319522`](#source-ctg-observation-nct00008528-2005-06-24-dd6e8c319522))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00008528-2005-06-24-dd6e8c319522`](#source-ctg-observation-nct00008528-2005-06-24-dd6e8c319522))

### Sources

<a id="source-ctg-observation-nct00008528-2005-06-24-dd6e8c319522"></a>
- **ClinicalTrials.gov record NCT00008528 · retained source version 2005-06-24:dd6e8c319522fc556747e18e467e15419f85b9ba2e12fe2adf64fa3506911bfb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00008528) (`ctg-observation-nct00008528-2005-06-24-dd6e8c319522`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00008528." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00008528-enfuvirtide-v1 SHA-256: d1f904f20084f2fb7d2aab22ecdd6ec3de0d220af639a240d1c6b70b33ab79a6.

---

<a id="clinicaltrials-gov-nct00021554-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00021554

> PeptideScanner retained ClinicalTrials.gov record NCT00021554 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00021554-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00021554-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00021554-enfuvirtide-v1
- Content SHA-256: `5a489a8a02b89e4e482444e3447e518a60dba4fcfe6c327654f15cce5abe5145`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00021554 ([`ctg-observation-nct00021554-2005-06-24-3465a28a381d`](#source-ctg-observation-nct00021554-2005-06-24-3465a28a381d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00021554 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00021554-2005-06-24-3465a28a381d`](#source-ctg-observation-nct00021554-2005-06-24-3465a28a381d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00021554 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00021554-2005-06-24-3465a28a381d`](#source-ctg-observation-nct00021554-2005-06-24-3465a28a381d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00021554-2005-06-24-3465a28a381d`](#source-ctg-observation-nct00021554-2005-06-24-3465a28a381d))

### Sources

<a id="source-ctg-observation-nct00021554-2005-06-24-3465a28a381d"></a>
- **ClinicalTrials.gov record NCT00021554 · retained source version 2005-06-24:3465a28a381d8821b88c50374275fcd5db6dee6462a5e221f69f4959addb8d41** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00021554) (`ctg-observation-nct00021554-2005-06-24-3465a28a381d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00021554." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00021554-enfuvirtide-v1 SHA-256: 5a489a8a02b89e4e482444e3447e518a60dba4fcfe6c327654f15cce5abe5145.

---

<a id="clinicaltrials-gov-nct00022763-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00022763

> PeptideScanner retained ClinicalTrials.gov record NCT00022763 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-02-15, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00022763-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-02-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00022763-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00022763-enfuvirtide-v1
- Content SHA-256: `a95a890444af9023c96a320637c47c81b22e5a58318d74a31d2c1ce7dd36b446`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00022763 ([`ctg-observation-nct00022763-2016-02-15-4e9114ad4efc`](#source-ctg-observation-nct00022763-2016-02-15-4e9114ad4efc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00022763 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-02-15, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00022763-2016-02-15-4e9114ad4efc`](#source-ctg-observation-nct00022763-2016-02-15-4e9114ad4efc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00022763 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-02-15, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00022763-2016-02-15-4e9114ad4efc`](#source-ctg-observation-nct00022763-2016-02-15-4e9114ad4efc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00022763-2016-02-15-4e9114ad4efc`](#source-ctg-observation-nct00022763-2016-02-15-4e9114ad4efc))

### Sources

<a id="source-ctg-observation-nct00022763-2016-02-15-4e9114ad4efc"></a>
- **ClinicalTrials.gov record NCT00022763 · retained source version 2016-02-15:4e9114ad4efcaed8592291314da760b10453881295006df34bdc60a235d3eb59** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00022763) (`ctg-observation-nct00022763-2016-02-15-4e9114ad4efc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00022763." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00022763-enfuvirtide-v1 SHA-256: a95a890444af9023c96a320637c47c81b22e5a58318d74a31d2c1ce7dd36b446.

---

<a id="clinicaltrials-gov-nct00031044-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00031044

> PeptideScanner retained ClinicalTrials.gov record NCT00031044 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00031044-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00031044-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00031044-enfuvirtide-v1
- Content SHA-256: `2d865c8250ad2e75cc22c602773d0af32013a5355d0207826ea3c8a4292d24ab`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00031044 ([`ctg-observation-nct00031044-2021-11-01-fab0ed3120ba`](#source-ctg-observation-nct00031044-2021-11-01-fab0ed3120ba))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00031044 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00031044-2021-11-01-fab0ed3120ba`](#source-ctg-observation-nct00031044-2021-11-01-fab0ed3120ba))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00031044 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00031044-2021-11-01-fab0ed3120ba`](#source-ctg-observation-nct00031044-2021-11-01-fab0ed3120ba))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00031044-2021-11-01-fab0ed3120ba`](#source-ctg-observation-nct00031044-2021-11-01-fab0ed3120ba))

### Sources

<a id="source-ctg-observation-nct00031044-2021-11-01-fab0ed3120ba"></a>
- **ClinicalTrials.gov record NCT00031044 · retained source version 2021-11-01:fab0ed3120bae77b95c27c551285a30e8b7edbaa370f64e7bcfe4beacb18adad** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00031044) (`ctg-observation-nct00031044-2021-11-01-fab0ed3120ba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00031044." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00031044-enfuvirtide-v1 SHA-256: 2d865c8250ad2e75cc22c602773d0af32013a5355d0207826ea3c8a4292d24ab.

---

<a id="clinicaltrials-gov-nct00051831-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00051831

> PeptideScanner retained ClinicalTrials.gov record NCT00051831 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00051831-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00051831-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00051831-enfuvirtide-v1
- Content SHA-256: `c816e73b2e9f27f435a7abc9e55b073316aeb2a4400f5c0034fe6b35c5f5c02b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00051831 ([`ctg-observation-nct00051831-2021-11-01-4d5321706c70`](#source-ctg-observation-nct00051831-2021-11-01-4d5321706c70))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00051831 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00051831-2021-11-01-4d5321706c70`](#source-ctg-observation-nct00051831-2021-11-01-4d5321706c70))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00051831 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00051831-2021-11-01-4d5321706c70`](#source-ctg-observation-nct00051831-2021-11-01-4d5321706c70))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00051831-2021-11-01-4d5321706c70`](#source-ctg-observation-nct00051831-2021-11-01-4d5321706c70))

### Sources

<a id="source-ctg-observation-nct00051831-2021-11-01-4d5321706c70"></a>
- **ClinicalTrials.gov record NCT00051831 · retained source version 2021-11-01:4d5321706c70f3643b9f993a8fbb1465eee99d7b5b7812274a13ce9210d21bc4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00051831) (`ctg-observation-nct00051831-2021-11-01-4d5321706c70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00051831." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00051831-enfuvirtide-v1 SHA-256: c816e73b2e9f27f435a7abc9e55b073316aeb2a4400f5c0034fe6b35c5f5c02b.

---

<a id="clinicaltrials-gov-nct00086710-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00086710

> PeptideScanner retained ClinicalTrials.gov record NCT00086710 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00086710-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2005-06-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00086710-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00086710-enfuvirtide-v1
- Content SHA-256: `6b162bd95245c937e8548fd6a309d153f4294060de58ac7d27a6a947eec99ad1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00086710 ([`ctg-observation-nct00086710-2005-06-24-8222e7950704`](#source-ctg-observation-nct00086710-2005-06-24-8222e7950704))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00086710 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00086710-2005-06-24-8222e7950704`](#source-ctg-observation-nct00086710-2005-06-24-8222e7950704))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00086710 at 2026-11-16T01:41:15.051Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00086710-2005-06-24-8222e7950704`](#source-ctg-observation-nct00086710-2005-06-24-8222e7950704))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00086710-2005-06-24-8222e7950704`](#source-ctg-observation-nct00086710-2005-06-24-8222e7950704))

### Sources

<a id="source-ctg-observation-nct00086710-2005-06-24-8222e7950704"></a>
- **ClinicalTrials.gov record NCT00086710 · retained source version 2005-06-24:8222e7950704745a9062ab28ec73f793e642f39c20afb4e39a01833037dae9f6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00086710) (`ctg-observation-nct00086710-2005-06-24-8222e7950704`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00086710." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00086710-enfuvirtide-v1 SHA-256: 6b162bd95245c937e8548fd6a309d153f4294060de58ac7d27a6a947eec99ad1.

---

<a id="clinicaltrials-gov-nct00120367-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00120367

> PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00120367-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00120367-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00120367-enfuvirtide-v1
- Content SHA-256: `a4288893a1ce51fd0895bd2a7d31a8543963b878b23a3729eb996d94ffc7fd70`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00120367 ([`ctg-observation-nct00120367-2026-04-02-27f7d866422b`](#source-ctg-observation-nct00120367-2026-04-02-27f7d866422b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00120367-2026-04-02-27f7d866422b`](#source-ctg-observation-nct00120367-2026-04-02-27f7d866422b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00120367 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-02, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00120367-2026-04-02-27f7d866422b`](#source-ctg-observation-nct00120367-2026-04-02-27f7d866422b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00120367-2026-04-02-27f7d866422b`](#source-ctg-observation-nct00120367-2026-04-02-27f7d866422b))

### Sources

<a id="source-ctg-observation-nct00120367-2026-04-02-27f7d866422b"></a>
- **ClinicalTrials.gov record NCT00120367 · retained source version 2026-04-02:27f7d866422bfff5535e5ca921a6dd68cf313a64af11d77f9ef922e183428034** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00120367) (`ctg-observation-nct00120367-2026-04-02-27f7d866422b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00120367." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00120367-enfuvirtide-v1 SHA-256: a4288893a1ce51fd0895bd2a7d31a8543963b878b23a3729eb996d94ffc7fd70.

---

<a id="clinicaltrials-gov-nct00302822-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00302822

> PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00302822-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00302822-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00302822-enfuvirtide-v1
- Content SHA-256: `0c8e55bee661d9949febc91926cb7ab0ecba84cbc77919efe7447c59bc2a6aad`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00302822 ([`ctg-observation-nct00302822-2026-04-07-3768e795d56f`](#source-ctg-observation-nct00302822-2026-04-07-3768e795d56f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00302822-2026-04-07-3768e795d56f`](#source-ctg-observation-nct00302822-2026-04-07-3768e795d56f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00302822 at 2026-11-16T01:41:15.051Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00302822-2026-04-07-3768e795d56f`](#source-ctg-observation-nct00302822-2026-04-07-3768e795d56f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00302822-2026-04-07-3768e795d56f`](#source-ctg-observation-nct00302822-2026-04-07-3768e795d56f))

### Sources

<a id="source-ctg-observation-nct00302822-2026-04-07-3768e795d56f"></a>
- **ClinicalTrials.gov record NCT00302822 · retained source version 2026-04-07:3768e795d56f3248b97a46840586142f18122230308d4de01cda70bec63155f9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00302822) (`ctg-observation-nct00302822-2026-04-07-3768e795d56f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00302822." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00302822-enfuvirtide-v1 SHA-256: 0c8e55bee661d9949febc91926cb7ab0ecba84cbc77919efe7447c59bc2a6aad.

---

<a id="clinicaltrials-gov-nct00334022-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00334022

> PeptideScanner retained ClinicalTrials.gov record NCT00334022 at 2026-11-16T01:41:15.051Z. Its registry update date was 2012-06-05, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00334022-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00334022-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00334022-enfuvirtide-v1
- Content SHA-256: `46d00e87f934a3bea1d0ae8a75e0d3ba07161df7928b959fe2d5128ecba3a956`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00334022 ([`ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4`](#source-ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00334022 at 2026-11-16T01:41:15.051Z. Its registry update date was 2012-06-05, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4`](#source-ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00334022 at 2026-11-16T01:41:15.051Z. Its registry update date was 2012-06-05, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4`](#source-ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4`](#source-ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4))

### Sources

<a id="source-ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4"></a>
- **ClinicalTrials.gov record NCT00334022 · retained source version 2012-06-05:bcef69c2dfe414d4c461a3902f17f1d8bf1b84933b55afca1bb77c0cff13de48** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00334022) (`ctg-observation-nct00334022-2012-06-05-bcef69c2dfe4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00334022." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00334022-enfuvirtide-v1 SHA-256: 46d00e87f934a3bea1d0ae8a75e0d3ba07161df7928b959fe2d5128ecba3a956.

---

<a id="clinicaltrials-gov-nct00344760-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00344760

> PeptideScanner retained ClinicalTrials.gov record NCT00344760 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00344760-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00344760-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00344760-enfuvirtide-v1
- Content SHA-256: `7e8a7e34ab028e39ebaeb346f454a0b775c444bf18743b5f60c8ecb22bc722e3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00344760 ([`ctg-observation-nct00344760-2021-05-11-5e9da1b635c7`](#source-ctg-observation-nct00344760-2021-05-11-5e9da1b635c7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00344760 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00344760-2021-05-11-5e9da1b635c7`](#source-ctg-observation-nct00344760-2021-05-11-5e9da1b635c7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00344760 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00344760-2021-05-11-5e9da1b635c7`](#source-ctg-observation-nct00344760-2021-05-11-5e9da1b635c7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00344760-2021-05-11-5e9da1b635c7`](#source-ctg-observation-nct00344760-2021-05-11-5e9da1b635c7))

### Sources

<a id="source-ctg-observation-nct00344760-2021-05-11-5e9da1b635c7"></a>
- **ClinicalTrials.gov record NCT00344760 · retained source version 2021-05-11:5e9da1b635c74bf756372c9e9a84d98d0a146018387d68755f769ca73930713c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00344760) (`ctg-observation-nct00344760-2021-05-11-5e9da1b635c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00344760." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00344760-enfuvirtide-v1 SHA-256: 7e8a7e34ab028e39ebaeb346f454a0b775c444bf18743b5f60c8ecb22bc722e3.

---

<a id="clinicaltrials-gov-nct00460382-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00460382

> PeptideScanner retained ClinicalTrials.gov record NCT00460382 at 2026-11-16T01:41:15.051Z. Its registry update date was 2010-09-17, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00460382-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-09-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00460382-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00460382-enfuvirtide-v1
- Content SHA-256: `dd74761005d76291f6795cdda3edb416ec420fc745adfeded461f9d2583ae795`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00460382 ([`ctg-observation-nct00460382-2010-09-17-bcaf153eeb94`](#source-ctg-observation-nct00460382-2010-09-17-bcaf153eeb94))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00460382 at 2026-11-16T01:41:15.051Z. Its registry update date was 2010-09-17, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00460382-2010-09-17-bcaf153eeb94`](#source-ctg-observation-nct00460382-2010-09-17-bcaf153eeb94))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00460382 at 2026-11-16T01:41:15.051Z. Its registry update date was 2010-09-17, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00460382-2010-09-17-bcaf153eeb94`](#source-ctg-observation-nct00460382-2010-09-17-bcaf153eeb94))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00460382-2010-09-17-bcaf153eeb94`](#source-ctg-observation-nct00460382-2010-09-17-bcaf153eeb94))

### Sources

<a id="source-ctg-observation-nct00460382-2010-09-17-bcaf153eeb94"></a>
- **ClinicalTrials.gov record NCT00460382 · retained source version 2010-09-17:bcaf153eeb94a40a4ef3ffc559885557f5664536cdffbe577748a1a7df6d7586** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00460382) (`ctg-observation-nct00460382-2010-09-17-bcaf153eeb94`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00460382." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00460382-enfuvirtide-v1 SHA-256: dd74761005d76291f6795cdda3edb416ec420fc745adfeded461f9d2583ae795.

---

<a id="clinicaltrials-gov-nct00487188-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00487188

> PeptideScanner retained ClinicalTrials.gov record NCT00487188 at 2026-11-16T01:41:15.051Z. Its registry update date was 2015-08-13, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00487188-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00487188-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00487188-enfuvirtide-v1
- Content SHA-256: `2f04e9cd46b2102ba321407154a1186fc084ae226493cf141700378e4611d676`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00487188 ([`ctg-observation-nct00487188-2015-08-13-ea13de1d9501`](#source-ctg-observation-nct00487188-2015-08-13-ea13de1d9501))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00487188 at 2026-11-16T01:41:15.051Z. Its registry update date was 2015-08-13, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00487188-2015-08-13-ea13de1d9501`](#source-ctg-observation-nct00487188-2015-08-13-ea13de1d9501))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00487188 at 2026-11-16T01:41:15.051Z. Its registry update date was 2015-08-13, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00487188-2015-08-13-ea13de1d9501`](#source-ctg-observation-nct00487188-2015-08-13-ea13de1d9501))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00487188-2015-08-13-ea13de1d9501`](#source-ctg-observation-nct00487188-2015-08-13-ea13de1d9501))

### Sources

<a id="source-ctg-observation-nct00487188-2015-08-13-ea13de1d9501"></a>
- **ClinicalTrials.gov record NCT00487188 · retained source version 2015-08-13:ea13de1d95011cfc4ffb4b484d5b1fb279cc3c4c14a1e47960468102191c8419** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00487188) (`ctg-observation-nct00487188-2015-08-13-ea13de1d9501`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00487188." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00487188-enfuvirtide-v1 SHA-256: 2f04e9cd46b2102ba321407154a1186fc084ae226493cf141700378e4611d676.

---

<a id="clinicaltrials-gov-nct00537394-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00537394

> PeptideScanner retained ClinicalTrials.gov record NCT00537394 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-04, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00537394-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00537394-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00537394-enfuvirtide-v1
- Content SHA-256: `2f64419a20567eab5b007a440596fe8b79bcbda07d6709c1cca31b06b98b5e13`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00537394 ([`ctg-observation-nct00537394-2021-11-04-8dddd104ba81`](#source-ctg-observation-nct00537394-2021-11-04-8dddd104ba81))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00537394 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-04, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00537394-2021-11-04-8dddd104ba81`](#source-ctg-observation-nct00537394-2021-11-04-8dddd104ba81))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00537394 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-04, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00537394-2021-11-04-8dddd104ba81`](#source-ctg-observation-nct00537394-2021-11-04-8dddd104ba81))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00537394-2021-11-04-8dddd104ba81`](#source-ctg-observation-nct00537394-2021-11-04-8dddd104ba81))

### Sources

<a id="source-ctg-observation-nct00537394-2021-11-04-8dddd104ba81"></a>
- **ClinicalTrials.gov record NCT00537394 · retained source version 2021-11-04:8dddd104ba8161b8418fd75536cdb3645ec6eb407fbe50b27bd5f2e490b76de2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00537394) (`ctg-observation-nct00537394-2021-11-04-8dddd104ba81`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00537394." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00537394-enfuvirtide-v1 SHA-256: 2f64419a20567eab5b007a440596fe8b79bcbda07d6709c1cca31b06b98b5e13.

---

<a id="clinicaltrials-gov-nct00624195-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00624195

> PeptideScanner retained ClinicalTrials.gov record NCT00624195 at 2026-11-16T01:41:15.051Z. Its registry update date was 2014-04-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00624195-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-04-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00624195-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00624195-enfuvirtide-v1
- Content SHA-256: `a438d211397db1e3d0f1213a578ee7e7a5af58dd967b37b6008fd7fec6f7bc0d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00624195 ([`ctg-observation-nct00624195-2014-04-23-9cca1c624c3e`](#source-ctg-observation-nct00624195-2014-04-23-9cca1c624c3e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00624195 at 2026-11-16T01:41:15.051Z. Its registry update date was 2014-04-23, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00624195-2014-04-23-9cca1c624c3e`](#source-ctg-observation-nct00624195-2014-04-23-9cca1c624c3e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00624195 at 2026-11-16T01:41:15.051Z. Its registry update date was 2014-04-23, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00624195-2014-04-23-9cca1c624c3e`](#source-ctg-observation-nct00624195-2014-04-23-9cca1c624c3e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00624195-2014-04-23-9cca1c624c3e`](#source-ctg-observation-nct00624195-2014-04-23-9cca1c624c3e))

### Sources

<a id="source-ctg-observation-nct00624195-2014-04-23-9cca1c624c3e"></a>
- **ClinicalTrials.gov record NCT00624195 · retained source version 2014-04-23:9cca1c624c3e1ab850c22751e54f59fe7f3d40ab32d2a90a650488b7bbd4ea0d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00624195) (`ctg-observation-nct00624195-2014-04-23-9cca1c624c3e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00624195." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00624195-enfuvirtide-v1 SHA-256: a438d211397db1e3d0f1213a578ee7e7a5af58dd967b37b6008fd7fec6f7bc0d.

---

<a id="clinicaltrials-gov-nct00657761-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT00657761

> PeptideScanner retained ClinicalTrials.gov record NCT00657761 at 2026-11-16T01:41:15.051Z. Its registry update date was 2008-04-14, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct00657761-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-04-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00657761-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00657761-enfuvirtide-v1
- Content SHA-256: `2e176fb2d1cb535eba8ba62e78be757df231481c148ac11cde3375c2281533d6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00657761 ([`ctg-observation-nct00657761-2008-04-14-834a440dfe79`](#source-ctg-observation-nct00657761-2008-04-14-834a440dfe79))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00657761 at 2026-11-16T01:41:15.051Z. Its registry update date was 2008-04-14, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00657761-2008-04-14-834a440dfe79`](#source-ctg-observation-nct00657761-2008-04-14-834a440dfe79))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00657761 at 2026-11-16T01:41:15.051Z. Its registry update date was 2008-04-14, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct00657761-2008-04-14-834a440dfe79`](#source-ctg-observation-nct00657761-2008-04-14-834a440dfe79))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00657761-2008-04-14-834a440dfe79`](#source-ctg-observation-nct00657761-2008-04-14-834a440dfe79))

### Sources

<a id="source-ctg-observation-nct00657761-2008-04-14-834a440dfe79"></a>
- **ClinicalTrials.gov record NCT00657761 · retained source version 2008-04-14:834a440dfe79d2c4c734283eb7ae9b0056803894533d0134fb1420e613ddcd40** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00657761) (`ctg-observation-nct00657761-2008-04-14-834a440dfe79`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00657761." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct00657761-enfuvirtide-v1 SHA-256: 2e176fb2d1cb535eba8ba62e78be757df231481c148ac11cde3375c2281533d6.

---

<a id="clinicaltrials-gov-nct01836068-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT01836068

> PeptideScanner retained ClinicalTrials.gov record NCT01836068 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct01836068-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01836068-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct01836068-enfuvirtide-v1
- Content SHA-256: `370c9020defdcdb119ae25eac0f2084b320b8fec48e1a5f0352905c93c36e2f0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01836068 ([`ctg-observation-nct01836068-2021-11-23-5a90c1792fb4`](#source-ctg-observation-nct01836068-2021-11-23-5a90c1792fb4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01836068 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-23, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct01836068-2021-11-23-5a90c1792fb4`](#source-ctg-observation-nct01836068-2021-11-23-5a90c1792fb4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01836068 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-23, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct01836068-2021-11-23-5a90c1792fb4`](#source-ctg-observation-nct01836068-2021-11-23-5a90c1792fb4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01836068-2021-11-23-5a90c1792fb4`](#source-ctg-observation-nct01836068-2021-11-23-5a90c1792fb4))

### Sources

<a id="source-ctg-observation-nct01836068-2021-11-23-5a90c1792fb4"></a>
- **ClinicalTrials.gov record NCT01836068 · retained source version 2021-11-23:5a90c1792fb4718e9dee924e74917ebb0bb2c65c17e8801aea3beb43badc1ad6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01836068) (`ctg-observation-nct01836068-2021-11-23-5a90c1792fb4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01836068." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct01836068-enfuvirtide-v1 SHA-256: 370c9020defdcdb119ae25eac0f2084b320b8fec48e1a5f0352905c93c36e2f0.

---

<a id="clinicaltrials-gov-nct02569502-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT02569502

> PeptideScanner retained ClinicalTrials.gov record NCT02569502 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-11-02, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct02569502-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-11-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02569502-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct02569502-enfuvirtide-v1
- Content SHA-256: `64f2f806efc067b999c26ce1b89282afe52b638ff883fa77a6e3f3edca3e6b56`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02569502 ([`ctg-observation-nct02569502-2016-11-02-ac25e142785a`](#source-ctg-observation-nct02569502-2016-11-02-ac25e142785a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02569502 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-11-02, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct02569502-2016-11-02-ac25e142785a`](#source-ctg-observation-nct02569502-2016-11-02-ac25e142785a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02569502 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-11-02, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct02569502-2016-11-02-ac25e142785a`](#source-ctg-observation-nct02569502-2016-11-02-ac25e142785a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02569502-2016-11-02-ac25e142785a`](#source-ctg-observation-nct02569502-2016-11-02-ac25e142785a))

### Sources

<a id="source-ctg-observation-nct02569502-2016-11-02-ac25e142785a"></a>
- **ClinicalTrials.gov record NCT02569502 · retained source version 2016-11-02:ac25e142785a46ab77881fd4cbae0746cc4cceee66caefbd0a20ba52fcf0d501** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02569502) (`ctg-observation-nct02569502-2016-11-02-ac25e142785a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02569502." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct02569502-enfuvirtide-v1 SHA-256: 64f2f806efc067b999c26ce1b89282afe52b638ff883fa77a6e3f3edca3e6b56.

---

<a id="clinicaltrials-gov-nct02582983-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT02582983

> PeptideScanner retained ClinicalTrials.gov record NCT02582983 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-07-06, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct02582983-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02582983-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct02582983-enfuvirtide-v1
- Content SHA-256: `729f30861c336e316a22f92d4bdfa7ac0f6ac95007e56a2f7fce4d5b2bf004bc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02582983 ([`ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1`](#source-ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02582983 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-07-06, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1`](#source-ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02582983 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-07-06, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1`](#source-ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1`](#source-ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1))

### Sources

<a id="source-ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1"></a>
- **ClinicalTrials.gov record NCT02582983 · retained source version 2016-07-06:a8e7be9e30b1cb6ef65b72a5cfc3d9544c31474f7d9693337a37fb95f489d223** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02582983) (`ctg-observation-nct02582983-2016-07-06-a8e7be9e30b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02582983." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct02582983-enfuvirtide-v1 SHA-256: 729f30861c336e316a22f92d4bdfa7ac0f6ac95007e56a2f7fce4d5b2bf004bc.

---

<a id="clinicaltrials-gov-nct02733419-enfuvirtide-v1"></a>

## ClinicalTrials.gov record NCT02733419

> PeptideScanner retained ClinicalTrials.gov record NCT02733419 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-04-11, and PeptideScanner's reviewed identity mapping was enfuvirtide.

- Evidence object: `story:clinicaltrials-gov-nct02733419-enfuvirtide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02733419-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct02733419-enfuvirtide-v1
- Content SHA-256: `631a6c1b1e01acd3a43a0eee2837b17a06bc406faefc0ca10c3443b81c494f44`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02733419 ([`ctg-observation-nct02733419-2016-04-11-a1f778e9bae2`](#source-ctg-observation-nct02733419-2016-04-11-a1f778e9bae2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02733419 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-04-11, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct02733419-2016-04-11-a1f778e9bae2`](#source-ctg-observation-nct02733419-2016-04-11-a1f778e9bae2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02733419 at 2026-11-16T01:41:15.051Z. Its registry update date was 2016-04-11, and PeptideScanner's reviewed identity mapping was enfuvirtide. ([`ctg-observation-nct02733419-2016-04-11-a1f778e9bae2`](#source-ctg-observation-nct02733419-2016-04-11-a1f778e9bae2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02733419-2016-04-11-a1f778e9bae2`](#source-ctg-observation-nct02733419-2016-04-11-a1f778e9bae2))

### Sources

<a id="source-ctg-observation-nct02733419-2016-04-11-a1f778e9bae2"></a>
- **ClinicalTrials.gov record NCT02733419 · retained source version 2016-04-11:a1f778e9bae2c891f80c65fcb201368c6f1add80aed42199a921a2bbbe71426e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02733419) (`ctg-observation-nct02733419-2016-04-11-a1f778e9bae2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02733419." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#clinicaltrials-gov-nct02733419-enfuvirtide-v1 SHA-256: 631a6c1b1e01acd3a43a0eee2837b17a06bc406faefc0ca10c3443b81c494f44.

---

<a id="fda-drugs-nda021481-v1"></a>

## Drugs@FDA application NDA021481

> The official Drugs@FDA dataset lists original submission 1 for NDA 021481 with status AP dated 2003-03-13, and names enfuvirtide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021481:v1`
- Evidence domain: Regulatory
- Date in source: 2003-03-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021481/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#fda-drugs-nda021481-v1
- Content SHA-256: `7a66b69b0dea887e8067794887b8457d2308e69562504f0426fcb4368b4aedee`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021481 ([`fda-drugs-nda021481-2003-03-13-3c03150391a1`](#source-fda-drugs-nda021481-2003-03-13-3c03150391a1))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021481 with status AP dated 2003-03-13, and names enfuvirtide among the application record's active ingredients. ([`fda-drugs-nda021481-2003-03-13-3c03150391a1`](#source-fda-drugs-nda021481-2003-03-13-3c03150391a1))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021481 with status AP dated 2003-03-13, and names enfuvirtide among the application record's active ingredients. ([`fda-drugs-nda021481-2003-03-13-3c03150391a1`](#source-fda-drugs-nda021481-2003-03-13-3c03150391a1))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021481-2003-03-13-3c03150391a1`](#source-fda-drugs-nda021481-2003-03-13-3c03150391a1))

### Sources

<a id="source-fda-drugs-nda021481-2003-03-13-3c03150391a1"></a>
- **Drugs@FDA application NDA021481 · original submission status AP · 2003-03-13 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021481%22&limit=1) (`fda-drugs-nda021481-2003-03-13-3c03150391a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021481." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#fda-drugs-nda021481-v1 SHA-256: 7a66b69b0dea887e8067794887b8457d2308e69562504f0426fcb4368b4aedee.

---

<a id="federal-register-e6-15554-v1"></a>

## Federal Register notice E6-15554

> The Federal Register published notice E6-15554, attributed to FDA and its parent HHS department, on 2006-09-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON,” and PeptideScanner's exact reviewed identity mapping connects the document to Enfuvirtide.

- Evidence object: `story:federal-register-e6-15554:v1`
- Evidence domain: Regulatory
- Date in source: 2006-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-15554/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#federal-register-e6-15554-v1
- Content SHA-256: `d3ca94cfc44ff47fa03c8431e884806d4028db48cf767274895a659a5b2581d5`

### Claims and source pins

#### Headline

Federal Register notice E6-15554 ([`federal-register-e6-15554-47aa15e45ba4`](#source-federal-register-e6-15554-47aa15e45ba4))

#### Summary

The Federal Register published notice E6-15554, attributed to FDA and its parent HHS department, on 2006-09-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON,” and PeptideScanner's exact reviewed identity mapping connects the document to Enfuvirtide. ([`federal-register-e6-15554-47aa15e45ba4`](#source-federal-register-e6-15554-47aa15e45ba4))

#### Paragraph 1

The Federal Register published notice E6-15554, attributed to FDA and its parent HHS department, on 2006-09-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON,” and PeptideScanner's exact reviewed identity mapping connects the document to Enfuvirtide. ([`federal-register-e6-15554-47aa15e45ba4`](#source-federal-register-e6-15554-47aa15e45ba4))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-15554-47aa15e45ba4`](#source-federal-register-e6-15554-47aa15e45ba4))

### Sources

<a id="source-federal-register-e6-15554-47aa15e45ba4"></a>
- **Federal Register notice E6-15554 · published 2006-09-20 · Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15554.pdf) (`federal-register-e6-15554-47aa15e45ba4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-15554." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#federal-register-e6-15554-v1 SHA-256: d3ca94cfc44ff47fa03c8431e884806d4028db48cf767274895a659a5b2581d5.

---

<a id="pubmed-pmid-12457443-enfuvirtide-v1"></a>

## Enfuvirtide.

> PubMed lists PMID 12457443 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12457443-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12457443-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-12457443-enfuvirtide-v1
- Content SHA-256: `a4260d2f3b38530c2aceda7ac01ceadf69fb01b6199949707eb11cd9b1e42116`

### Claims and source pins

#### Headline

Enfuvirtide. ([`pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e`](#source-pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e))

#### Summary

PubMed lists PMID 12457443 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e`](#source-pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e))

#### Paragraph 1

PubMed lists PMID 12457443 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2002-12 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e`](#source-pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e`](#source-pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e))

### Sources

<a id="source-pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e"></a>
- **Enfuvirtide. · retained source version 1:2019-09-16:current:c887a6d5f23e634fd90cec2d81928c8eade97ea3c9884244111d882bae08df3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12457443/) (`pubmed-observation-pmid-12457443-2019-09-16-c887a6d5f23e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-12457443-enfuvirtide-v1 SHA-256: a4260d2f3b38530c2aceda7ac01ceadf69fb01b6199949707eb11cd9b1e42116.

---

<a id="pubmed-pmid-12562683-enfuvirtide-v1"></a>

## Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.

> PubMed lists PMID 12562683 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2003-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12562683-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12562683-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-12562683-enfuvirtide-v1
- Content SHA-256: `833ba7d0ad7758c3e85d28c017dfd27a6cb31d5bc4246f2b28a043321e70050a`

### Claims and source pins

#### Headline

Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. ([`pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937`](#source-pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937))

#### Summary

PubMed lists PMID 12562683 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2003-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937`](#source-pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937))

#### Paragraph 1

PubMed lists PMID 12562683 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2003-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937`](#source-pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937`](#source-pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937))

### Sources

<a id="source-pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937"></a>
- **Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. · retained source version 1:2019-05-13:current:c5bd5afa69373c1a480036f18aace48d2f133affcfcf56d12124715cc4f2b175** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12562683/) (`pubmed-observation-pmid-12562683-2019-05-13-c5bd5afa6937`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-12562683-enfuvirtide-v1 SHA-256: 833ba7d0ad7758c3e85d28c017dfd27a6cb31d5bc4246f2b28a043321e70050a.

---

<a id="pubmed-pmid-14664654-enfuvirtide-v1"></a>

## Enfuvirtide.

> PubMed lists PMID 14664654 in Drugs as Journal Article, Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14664654-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14664654-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-14664654-enfuvirtide-v1
- Content SHA-256: `e58d4b9d89c825b16da80dd1b26f4a44fc6783027b4eec127ae43fd68dcfe317`

### Claims and source pins

#### Headline

Enfuvirtide. ([`pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d`](#source-pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d))

#### Summary

PubMed lists PMID 14664654 in Drugs as Journal Article, Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d`](#source-pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d))

#### Paragraph 1

PubMed lists PMID 14664654 in Drugs as Journal Article, Review, with publication-date metadata of 2003 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d`](#source-pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d`](#source-pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d))

### Sources

<a id="source-pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d"></a>
- **Enfuvirtide. · retained source version 1:2026-10-11:current:63d4effd0f7dbc2e3ca624106f0692b6f6e8c914d4b8e1257ac0537603edfd7e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14664654/) (`pubmed-observation-pmid-14664654-2026-10-11-63d4effd0f7d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-14664654-enfuvirtide-v1 SHA-256: e58d4b9d89c825b16da80dd1b26f4a44fc6783027b4eec127ae43fd68dcfe317.

---

<a id="pubmed-pmid-15002081-enfuvirtide-v1"></a>

## Enfuvirtide: antiretroviral class 4, drug 1.

> PubMed lists PMID 15002081 in HIV clinical trials as Journal Article, Review, with publication-date metadata of 2004 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15002081-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15002081-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15002081-enfuvirtide-v1
- Content SHA-256: `1089ecac0dcc023e7569c548ba7addcf7d7e65901914f738812fa1a3fef8e4b4`

### Claims and source pins

#### Headline

Enfuvirtide: antiretroviral class 4, drug 1. ([`pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1`](#source-pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1))

#### Summary

PubMed lists PMID 15002081 in HIV clinical trials as Journal Article, Review, with publication-date metadata of 2004 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1`](#source-pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1))

#### Paragraph 1

PubMed lists PMID 15002081 in HIV clinical trials as Journal Article, Review, with publication-date metadata of 2004 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1`](#source-pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1`](#source-pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1))

### Sources

<a id="source-pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1"></a>
- **Enfuvirtide: antiretroviral class 4, drug 1. · retained source version 1:2018-11-30:current:5cc8f6b50ba1be0bb653349c22e56366b734d283def110aee6fb02269ce7f15a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15002081/) (`pubmed-observation-pmid-15002081-2018-11-30-5cc8f6b50ba1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide: antiretroviral class 4, drug 1." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15002081-enfuvirtide-v1 SHA-256: 1089ecac0dcc023e7569c548ba7addcf7d7e65901914f738812fa1a3fef8e4b4.

---

<a id="pubmed-pmid-15148534-enfuvirtide-v1"></a>

## Enfuvirtide.

> PubMed lists PMID 15148534 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2004-03 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15148534-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15148534-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15148534-enfuvirtide-v1
- Content SHA-256: `74575232f2cc870ed03edb584799823e3374d11465e58a74569874e3bd466ba7`

### Claims and source pins

#### Headline

Enfuvirtide. ([`pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d`](#source-pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d))

#### Summary

PubMed lists PMID 15148534 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2004-03 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d`](#source-pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d))

#### Paragraph 1

PubMed lists PMID 15148534 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2004-03 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d`](#source-pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d`](#source-pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d))

### Sources

<a id="source-pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d"></a>
- **Enfuvirtide. · retained source version 1:2019-11-08:current:d6b8bd1c4d4de3decb0a19706bfc5ceafbed9b41d16beb42391e8cb35cc9912c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15148534/) (`pubmed-observation-pmid-15148534-2019-11-08-d6b8bd1c4d4d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15148534-enfuvirtide-v1 SHA-256: 74575232f2cc870ed03edb584799823e3374d11465e58a74569874e3bd466ba7.

---

<a id="pubmed-pmid-15199084-enfuvirtide-v1"></a>

## Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

> PubMed lists PMID 15199084 in Journal of clinical pharmacology as Clinical Trial, Journal Article, with publication-date metadata of 2004-07 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15199084-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15199084-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15199084-enfuvirtide-v1
- Content SHA-256: `33b6e124cd3fe64bc17aedfbf3306e3ead1703bf1463cb23bd7585a301d56a4a`

### Claims and source pins

#### Headline

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. ([`pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7`](#source-pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7))

#### Summary

PubMed lists PMID 15199084 in Journal of clinical pharmacology as Clinical Trial, Journal Article, with publication-date metadata of 2004-07 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7`](#source-pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7))

#### Paragraph 1

PubMed lists PMID 15199084 in Journal of clinical pharmacology as Clinical Trial, Journal Article, with publication-date metadata of 2004-07 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7`](#source-pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7`](#source-pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7))

### Sources

<a id="source-pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7"></a>
- **Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. · retained source version 1:2018-11-30:current:998b26b8e7a74c86af87a7e6e8a5c93c6cef6a1fbf1181522a5644ae67192aca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15199084/) (`pubmed-observation-pmid-15199084-2018-11-30-998b26b8e7a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15199084-enfuvirtide-v1 SHA-256: 33b6e124cd3fe64bc17aedfbf3306e3ead1703bf1463cb23bd7585a301d56a4a.

---

<a id="pubmed-pmid-15258964-enfuvirtide-v1"></a>

## Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

> PubMed lists PMID 15258964 in Journal of medical virology as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15258964-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15258964-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15258964-enfuvirtide-v1
- Content SHA-256: `3799064633559be686796fa164ac782f824969375aec0772ff60dcd1d46d10fb`

### Claims and source pins

#### Headline

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. ([`pubmed-observation-pmid-15258964-2018-11-30-722c05262627`](#source-pubmed-observation-pmid-15258964-2018-11-30-722c05262627))

#### Summary

PubMed lists PMID 15258964 in Journal of medical virology as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15258964-2018-11-30-722c05262627`](#source-pubmed-observation-pmid-15258964-2018-11-30-722c05262627))

#### Paragraph 1

PubMed lists PMID 15258964 in Journal of medical virology as Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15258964-2018-11-30-722c05262627`](#source-pubmed-observation-pmid-15258964-2018-11-30-722c05262627))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15258964-2018-11-30-722c05262627`](#source-pubmed-observation-pmid-15258964-2018-11-30-722c05262627))

### Sources

<a id="source-pubmed-observation-pmid-15258964-2018-11-30-722c05262627"></a>
- **Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. · retained source version 1:2018-11-30:current:722c052626278458f6af870f6a3b3414827c8bccdc5ba6fad4de20f35b250d0a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15258964/) (`pubmed-observation-pmid-15258964-2018-11-30-722c05262627`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15258964-enfuvirtide-v1 SHA-256: 3799064633559be686796fa164ac782f824969375aec0772ff60dcd1d46d10fb.

---

<a id="pubmed-pmid-15280778-enfuvirtide-v1"></a>

## Immunological and virological study of enfuvirtide-treated HIV-positive patients.

> PubMed lists PMID 15280778 in AIDS (London, England) as Clinical Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-08-20 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15280778-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15280778-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15280778-enfuvirtide-v1
- Content SHA-256: `f2486fac67a4221040218eef4dc41caf2fce7ae60ba231c5329dae12c2feca0d`

### Claims and source pins

#### Headline

Immunological and virological study of enfuvirtide-treated HIV-positive patients. ([`pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d`](#source-pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d))

#### Summary

PubMed lists PMID 15280778 in AIDS (London, England) as Clinical Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-08-20 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d`](#source-pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d))

#### Paragraph 1

PubMed lists PMID 15280778 in AIDS (London, England) as Clinical Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-08-20 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d`](#source-pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d`](#source-pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d))

### Sources

<a id="source-pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d"></a>
- **Immunological and virological study of enfuvirtide-treated HIV-positive patients. · retained source version 1:2019-07-18:current:ee8b6b94a60dbe77c7bae81cb85912b1201f126849b93b986e3f1d6fdc50ba22** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15280778/) (`pubmed-observation-pmid-15280778-2019-07-18-ee8b6b94a60d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Immunological and virological study of enfuvirtide-treated HIV-positive patients." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15280778-enfuvirtide-v1 SHA-256: f2486fac67a4221040218eef4dc41caf2fce7ae60ba231c5329dae12c2feca0d.

---

<a id="pubmed-pmid-15316339-enfuvirtide-v1"></a>

## Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.

> PubMed lists PMID 15316339 in AIDS (London, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2004-09-03 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15316339-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15316339-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15316339-enfuvirtide-v1
- Content SHA-256: `259c241ee519f663ab2cf80392cc28672f0892be658ee5616500b11ea5f64f20`

### Claims and source pins

#### Headline

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. ([`pubmed-observation-pmid-15316339-2019-07-18-e26df264b062`](#source-pubmed-observation-pmid-15316339-2019-07-18-e26df264b062))

#### Summary

PubMed lists PMID 15316339 in AIDS (London, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2004-09-03 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15316339-2019-07-18-e26df264b062`](#source-pubmed-observation-pmid-15316339-2019-07-18-e26df264b062))

#### Paragraph 1

PubMed lists PMID 15316339 in AIDS (London, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2004-09-03 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15316339-2019-07-18-e26df264b062`](#source-pubmed-observation-pmid-15316339-2019-07-18-e26df264b062))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15316339-2019-07-18-e26df264b062`](#source-pubmed-observation-pmid-15316339-2019-07-18-e26df264b062))

### Sources

<a id="source-pubmed-observation-pmid-15316339-2019-07-18-e26df264b062"></a>
- **Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. · retained source version 1:2019-07-18:current:e26df264b06289a7b1ff243935e36ca6da102e7200c594220a17c4e29944a86e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15316339/) (`pubmed-observation-pmid-15316339-2019-07-18-e26df264b062`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15316339-enfuvirtide-v1 SHA-256: 259c241ee519f663ab2cf80392cc28672f0892be658ee5616500b11ea5f64f20.

---

<a id="pubmed-pmid-15538017-enfuvirtide-v1"></a>

## Enfuvirtide (T-20): potentials and challenges.

> PubMed lists PMID 15538017 in The Journal of the Association of Nurses in AIDS Care : JANAC as Journal Article, Review, with publication-date metadata of 2004 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15538017-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15538017-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15538017-enfuvirtide-v1
- Content SHA-256: `12e175cf9a29dc3e0f6da095ca426b0eff4074d71bd0fa07ce4b0656fdc5ff92`

### Claims and source pins

#### Headline

Enfuvirtide (T-20): potentials and challenges. ([`pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74`](#source-pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74))

#### Summary

PubMed lists PMID 15538017 in The Journal of the Association of Nurses in AIDS Care : JANAC as Journal Article, Review, with publication-date metadata of 2004 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74`](#source-pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74))

#### Paragraph 1

PubMed lists PMID 15538017 in The Journal of the Association of Nurses in AIDS Care : JANAC as Journal Article, Review, with publication-date metadata of 2004 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74`](#source-pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74`](#source-pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74))

### Sources

<a id="source-pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74"></a>
- **Enfuvirtide (T-20): potentials and challenges. · retained source version 1:2018-12-01:current:a32c0e154a744abfb5e655468f6a13c6cc91a5ff9b868f0f856e33e9f68c3b67** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15538017/) (`pubmed-observation-pmid-15538017-2018-12-01-a32c0e154a74`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide (T-20): potentials and challenges." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15538017-enfuvirtide-v1 SHA-256: 12e175cf9a29dc3e0f6da095ca426b0eff4074d71bd0fa07ce4b0656fdc5ff92.

---

<a id="pubmed-pmid-15626952-enfuvirtide-v1"></a>

## Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.

> PubMed lists PMID 15626952 in The Pediatric infectious disease journal as Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15626952-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15626952-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15626952-enfuvirtide-v1
- Content SHA-256: `5f446214788722ddd3b26f53606ba5cffacf699472009f25deaafbe5babaa948`

### Claims and source pins

#### Headline

Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. ([`pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad`](#source-pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad))

#### Summary

PubMed lists PMID 15626952 in The Pediatric infectious disease journal as Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad`](#source-pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad))

#### Paragraph 1

PubMed lists PMID 15626952 in The Pediatric infectious disease journal as Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, and 1 more PubMed publication type, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad`](#source-pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad`](#source-pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad))

### Sources

<a id="source-pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad"></a>
- **Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. · retained source version 1:2018-12-01:current:0ec3b0024fad5a83842ff9926baebb784e65d0d22b9d91e6b00a2bcc9e40fd36** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15626952/) (`pubmed-observation-pmid-15626952-2018-12-01-0ec3b0024fad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15626952-enfuvirtide-v1 SHA-256: 5f446214788722ddd3b26f53606ba5cffacf699472009f25deaafbe5babaa948.

---

<a id="pubmed-pmid-15742551-enfuvirtide-v1"></a>

## \[Therapeutic indications, antiretroviral treatment optimization and quality of life of patients taking enfuvirtide\].

> PubMed lists PMID 15742551 in Medecine et maladies infectieuses as Journal Article, Review, with publication-date metadata of 2004-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15742551-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15742551-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15742551-enfuvirtide-v1
- Content SHA-256: `b7b856e5d7bc5c4a042e84d33ebb7421514ab0008d96e24a26cad0f3ad7110ee`

### Claims and source pins

#### Headline

\[Therapeutic indications, antiretroviral treatment optimization and quality of life of patients taking enfuvirtide\]. ([`pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544`](#source-pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544))

#### Summary

PubMed lists PMID 15742551 in Medecine et maladies infectieuses as Journal Article, Review, with publication-date metadata of 2004-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544`](#source-pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544))

#### Paragraph 1

PubMed lists PMID 15742551 in Medecine et maladies infectieuses as Journal Article, Review, with publication-date metadata of 2004-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544`](#source-pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544`](#source-pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544))

### Sources

<a id="source-pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544"></a>
- **\[Therapeutic indications, antiretroviral treatment optimization and quality of life of patients taking enfuvirtide\]. · retained source version 1:2018-12-01:current:5cf6b256b5440c1b05b884638cf2ca11afcd56a418ed7ab1623d9cbd8a6499ed** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15742551/) (`pubmed-observation-pmid-15742551-2018-12-01-5cf6b256b544`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Therapeutic indications, antiretroviral treatment optimization and quality of life of patients taking enfuvirtide\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-15742551-enfuvirtide-v1 SHA-256: b7b856e5d7bc5c4a042e84d33ebb7421514ab0008d96e24a26cad0f3ad7110ee.

---

<a id="pubmed-pmid-16433570-enfuvirtide-v1"></a>

## \[Enfuvirtide: first drug of a new family of antiretroviral agents\].

> PubMed lists PMID 16433570 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Journal Article, Review, with publication-date metadata of 2005 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16433570-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16433570-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-16433570-enfuvirtide-v1
- Content SHA-256: `1f3308c7ce8a904be2bb945e223195d9db5c3e8ebd05a35c24c4dc281e7624b5`

### Claims and source pins

#### Headline

\[Enfuvirtide: first drug of a new family of antiretroviral agents\]. ([`pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec`](#source-pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec))

#### Summary

PubMed lists PMID 16433570 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Journal Article, Review, with publication-date metadata of 2005 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec`](#source-pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec))

#### Paragraph 1

PubMed lists PMID 16433570 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Journal Article, Review, with publication-date metadata of 2005 Nov-Dec (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec`](#source-pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec`](#source-pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec))

### Sources

<a id="source-pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec"></a>
- **\[Enfuvirtide: first drug of a new family of antiretroviral agents\]. · retained source version 1:2019-11-09:current:092f9a5ab7ec13cb95f46908c1ee994d79414fcc73845f6d5ea7f3206224c24b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16433570/) (`pubmed-observation-pmid-16433570-2019-11-09-092f9a5ab7ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Enfuvirtide: first drug of a new family of antiretroviral agents\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-16433570-enfuvirtide-v1 SHA-256: 1f3308c7ce8a904be2bb945e223195d9db5c3e8ebd05a35c24c4dc281e7624b5.

---

<a id="pubmed-pmid-16706613-enfuvirtide-v1"></a>

## Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

> PubMed lists PMID 16706613 in AIDS research and human retroviruses as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-05 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16706613-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2006-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16706613-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-16706613-enfuvirtide-v1
- Content SHA-256: `14da540843e8d3aee6f67bbfabf7f4de23a6ce4dbc6656fce7e2a7f121d18b6b`

### Claims and source pins

#### Headline

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. ([`pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1`](#source-pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1))

#### Summary

PubMed lists PMID 16706613 in AIDS research and human retroviruses as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-05 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1`](#source-pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1))

#### Paragraph 1

PubMed lists PMID 16706613 in AIDS research and human retroviruses as Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-05 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1`](#source-pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1`](#source-pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1))

### Sources

<a id="source-pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1"></a>
- **Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. · retained source version 1:2006-11-15:current:d9fcb443dcd103f0208565862d7364956136fd39e76f80734d7d8da178fa8a39** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16706613/) (`pubmed-observation-pmid-16706613-2006-11-15-d9fcb443dcd1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-16706613-enfuvirtide-v1 SHA-256: 14da540843e8d3aee6f67bbfabf7f4de23a6ce4dbc6656fce7e2a7f121d18b6b.

---

<a id="pubmed-pmid-16759047-enfuvirtide-v1"></a>

## A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.

> PubMed lists PMID 16759047 in Antiviral therapy as Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16759047-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16759047-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-16759047-enfuvirtide-v1
- Content SHA-256: `3161b0ff7c2e3e7689683e1b1395f52f0fcec0e79ff30ebfbb45c7aa4c4d8c51`

### Claims and source pins

#### Headline

A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. ([`pubmed-observation-pmid-16759047-2018-12-01-58346b565f25`](#source-pubmed-observation-pmid-16759047-2018-12-01-58346b565f25))

#### Summary

PubMed lists PMID 16759047 in Antiviral therapy as Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16759047-2018-12-01-58346b565f25`](#source-pubmed-observation-pmid-16759047-2018-12-01-58346b565f25))

#### Paragraph 1

PubMed lists PMID 16759047 in Antiviral therapy as Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006 (year precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16759047-2018-12-01-58346b565f25`](#source-pubmed-observation-pmid-16759047-2018-12-01-58346b565f25))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16759047-2018-12-01-58346b565f25`](#source-pubmed-observation-pmid-16759047-2018-12-01-58346b565f25))

### Sources

<a id="source-pubmed-observation-pmid-16759047-2018-12-01-58346b565f25"></a>
- **A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. · retained source version 1:2018-12-01:current:58346b565f25c6741cc00fd2a130aa8c2dcb3c3f956750d9672c99e3d1e7a7bd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16759047/) (`pubmed-observation-pmid-16759047-2018-12-01-58346b565f25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-16759047-enfuvirtide-v1 SHA-256: 3161b0ff7c2e3e7689683e1b1395f52f0fcec0e79ff30ebfbb45c7aa4c4d8c51.

---

<a id="pubmed-pmid-17205468-enfuvirtide-v1"></a>

## Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?

> PubMed lists PMID 17205468 in The Journal of infectious diseases as Editorial, Review, Comment, with publication-date metadata of 2006-12-21 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17205468-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17205468-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17205468-enfuvirtide-v1
- Content SHA-256: `bb98f18562cefd9b476518a8c2c5ee84b2dc8a9712425591e8aa1caf443aa4cc`

### Claims and source pins

#### Headline

Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering? ([`pubmed-observation-pmid-17205468-2018-12-01-24797492415f`](#source-pubmed-observation-pmid-17205468-2018-12-01-24797492415f))

#### Summary

PubMed lists PMID 17205468 in The Journal of infectious diseases as Editorial, Review, Comment, with publication-date metadata of 2006-12-21 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17205468-2018-12-01-24797492415f`](#source-pubmed-observation-pmid-17205468-2018-12-01-24797492415f))

#### Paragraph 1

PubMed lists PMID 17205468 in The Journal of infectious diseases as Editorial, Review, Comment, with publication-date metadata of 2006-12-21 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17205468-2018-12-01-24797492415f`](#source-pubmed-observation-pmid-17205468-2018-12-01-24797492415f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17205468-2018-12-01-24797492415f`](#source-pubmed-observation-pmid-17205468-2018-12-01-24797492415f))

### Sources

<a id="source-pubmed-observation-pmid-17205468-2018-12-01-24797492415f"></a>
- **Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering? · retained source version 1:2018-12-01:current:24797492415fa8f805a5a35acd3b3c3f3271d72a0fa3df976d4122a118567238** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17205468/) (`pubmed-observation-pmid-17205468-2018-12-01-24797492415f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17205468-enfuvirtide-v1 SHA-256: bb98f18562cefd9b476518a8c2c5ee84b2dc8a9712425591e8aa1caf443aa4cc.

---

<a id="pubmed-pmid-17225316-enfuvirtide-v1"></a>

## Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).

> PubMed lists PMID 17225316 in TreatmentUpdate as Controlled Clinical Trial, Journal Article, Newspaper Article, with publication-date metadata of 2005 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17225316-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17225316-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17225316-enfuvirtide-v1
- Content SHA-256: `a45279d82ee7120481ba146cec82d27479883c0485bf1533b5bdf7680484f40d`

### Claims and source pins

#### Headline

Anti-HIV agents. T-20 (enfurvirtide, Fuzeon). ([`pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83`](#source-pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83))

#### Summary

PubMed lists PMID 17225316 in TreatmentUpdate as Controlled Clinical Trial, Journal Article, Newspaper Article, with publication-date metadata of 2005 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83`](#source-pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83))

#### Paragraph 1

PubMed lists PMID 17225316 in TreatmentUpdate as Controlled Clinical Trial, Journal Article, Newspaper Article, with publication-date metadata of 2005 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83`](#source-pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83`](#source-pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83))

### Sources

<a id="source-pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83"></a>
- **Anti-HIV agents. T-20 (enfurvirtide, Fuzeon). · retained source version 1:2018-12-01:current:cf32da3c6c8334461b05e5815641976973ee9a17d6b600956d3910ed1bc733e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17225316/) (`pubmed-observation-pmid-17225316-2018-12-01-cf32da3c6c83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Anti-HIV agents. T-20 (enfurvirtide, Fuzeon)." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17225316-enfuvirtide-v1 SHA-256: a45279d82ee7120481ba146cec82d27479883c0485bf1533b5bdf7680484f40d.

---

<a id="pubmed-pmid-17288910-enfuvirtide-v1"></a>

## \[Spanish recommendations for proper use of enfuvirtide\].

> PubMed lists PMID 17288910 in Enfermedades infecciosas y microbiologia clinica as Consensus Statement, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17288910-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17288910-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17288910-enfuvirtide-v1
- Content SHA-256: `3424f1390b60bbf1f18c541fd14de5cdd6cab364f789faf6cc06efc4d2c002ac`

### Claims and source pins

#### Headline

\[Spanish recommendations for proper use of enfuvirtide\]. ([`pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6`](#source-pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6))

#### Summary

PubMed lists PMID 17288910 in Enfermedades infecciosas y microbiologia clinica as Consensus Statement, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6`](#source-pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6))

#### Paragraph 1

PubMed lists PMID 17288910 in Enfermedades infecciosas y microbiologia clinica as Consensus Statement, Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2007-02 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6`](#source-pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6`](#source-pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6))

### Sources

<a id="source-pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6"></a>
- **\[Spanish recommendations for proper use of enfuvirtide\]. · retained source version 1:2026-01-28:current:25dd5606a2d6f79d9463cbde9a4a83498bb3a2ebc010da91dbc95bb2830a33d2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17288910/) (`pubmed-observation-pmid-17288910-2026-01-28-25dd5606a2d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Spanish recommendations for proper use of enfuvirtide\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17288910-enfuvirtide-v1 SHA-256: 3424f1390b60bbf1f18c541fd14de5cdd6cab364f789faf6cc06efc4d2c002ac.

---

<a id="pubmed-pmid-17389560-enfuvirtide-v1"></a>

## Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.

> PubMed lists PMID 17389560 in Journal of clinical pharmacology as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17389560-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17389560-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17389560-enfuvirtide-v1
- Content SHA-256: `a38a76c07afb2bf82d94c0d756e88f7090d684ed525bb43c3f7d1c19a86a5307`

### Claims and source pins

#### Headline

Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. ([`pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd`](#source-pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd))

#### Summary

PubMed lists PMID 17389560 in Journal of clinical pharmacology as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd`](#source-pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd))

#### Paragraph 1

PubMed lists PMID 17389560 in Journal of clinical pharmacology as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2007-04 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd`](#source-pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd`](#source-pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd))

### Sources

<a id="source-pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd"></a>
- **Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. · retained source version 1:2021-12-03:current:52d9d43c70bd2b766ec115c5c8ab7f049a65235f640c0aca3b416327d5042334** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17389560/) (`pubmed-observation-pmid-17389560-2021-12-03-52d9d43c70bd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-17389560-enfuvirtide-v1 SHA-256: a38a76c07afb2bf82d94c0d756e88f7090d684ed525bb43c3f7d1c19a86a5307.

---

<a id="pubmed-pmid-18710359-enfuvirtide-v1"></a>

## Reassessment of enfuvirtide's role in the management of HIV-1 infection.

> PubMed lists PMID 18710359 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2008-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18710359-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18710359-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-18710359-enfuvirtide-v1
- Content SHA-256: `2dc92149a3151d76d30cc37e2922ad6ccf93444d40e98c8f2a627ea9ffe232f2`

### Claims and source pins

#### Headline

Reassessment of enfuvirtide's role in the management of HIV-1 infection. ([`pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31`](#source-pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31))

#### Summary

PubMed lists PMID 18710359 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2008-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31`](#source-pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31))

#### Paragraph 1

PubMed lists PMID 18710359 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2008-09 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31`](#source-pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31`](#source-pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31))

### Sources

<a id="source-pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31"></a>
- **Reassessment of enfuvirtide's role in the management of HIV-1 infection. · retained source version 1:2019-09-17:current:6b1478ae9a31ac6208b999666bebf9e8fc4fbec308eed2d82bc88244f083ebb7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18710359/) (`pubmed-observation-pmid-18710359-2019-09-17-6b1478ae9a31`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Reassessment of enfuvirtide's role in the management of HIV-1 infection." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-18710359-enfuvirtide-v1 SHA-256: 2dc92149a3151d76d30cc37e2922ad6ccf93444d40e98c8f2a627ea9ffe232f2.

---

<a id="pubmed-pmid-19461505-enfuvirtide-v1"></a>

## Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.

> PubMed lists PMID 19461505 in AIDS (London, England) as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07-17 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19461505-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19461505-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-19461505-enfuvirtide-v1
- Content SHA-256: `6e6d2495db43e7cb60f17d78419903f980dff442c0ce6f690f93e6cfcdd75f07`

### Claims and source pins

#### Headline

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. ([`pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e`](#source-pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e))

#### Summary

PubMed lists PMID 19461505 in AIDS (London, England) as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07-17 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e`](#source-pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e))

#### Paragraph 1

PubMed lists PMID 19461505 in AIDS (London, England) as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-07-17 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e`](#source-pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e`](#source-pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e))

### Sources

<a id="source-pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e"></a>
- **Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. · retained source version 1:2026-05-18:current:903e5763f48e2432518c8509297eefe90916acdbac32ed312a436c9be642201e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19461505/) (`pubmed-observation-pmid-19461505-2026-05-18-903e5763f48e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-19461505-enfuvirtide-v1 SHA-256: 6e6d2495db43e7cb60f17d78419903f980dff442c0ce6f690f93e6cfcdd75f07.

---

<a id="pubmed-pmid-20001856-enfuvirtide-v1"></a>

## No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

> PubMed lists PMID 20001856 in The Journal of infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2010-01-15 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20001856-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20001856-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-20001856-enfuvirtide-v1
- Content SHA-256: `452f4b9daa51ea702be1dada42f428a02a1b7a87f4bf77b71fe3a66a2da549f1`

### Claims and source pins

#### Headline

No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. ([`pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5`](#source-pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5))

#### Summary

PubMed lists PMID 20001856 in The Journal of infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2010-01-15 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5`](#source-pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5))

#### Paragraph 1

PubMed lists PMID 20001856 in The Journal of infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2010-01-15 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5`](#source-pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5`](#source-pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5))

### Sources

<a id="source-pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5"></a>
- **No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. · retained source version 1:2025-05-29:current:f940377c57e5e33136bfd38f18a66226ef7647d1c70c5282b3829111fedcf89a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20001856/) (`pubmed-observation-pmid-20001856-2025-05-29-f940377c57e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-20001856-enfuvirtide-v1 SHA-256: 452f4b9daa51ea702be1dada42f428a02a1b7a87f4bf77b71fe3a66a2da549f1.

---

<a id="pubmed-pmid-20977403-enfuvirtide-v1"></a>

## Enfuvirtide: from basic investigations to current clinical use.

> PubMed lists PMID 20977403 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2010-11 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20977403-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20977403-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-20977403-enfuvirtide-v1
- Content SHA-256: `c908e4eec52f4c9b49a5c61e0e8dd2fb0003368dc09d76dc7370844a24a439e3`

### Claims and source pins

#### Headline

Enfuvirtide: from basic investigations to current clinical use. ([`pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531`](#source-pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531))

#### Summary

PubMed lists PMID 20977403 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2010-11 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531`](#source-pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531))

#### Paragraph 1

PubMed lists PMID 20977403 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2010-11 (month precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531`](#source-pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531`](#source-pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531))

### Sources

<a id="source-pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531"></a>
- **Enfuvirtide: from basic investigations to current clinical use. · retained source version 1:2018-12-01:current:6c63dfa7f5312e8913ca6d0225e34d13acc36cac18458869b8d432433aa987e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20977403/) (`pubmed-observation-pmid-20977403-2018-12-01-6c63dfa7f531`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide: from basic investigations to current clinical use." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-20977403-enfuvirtide-v1 SHA-256: c908e4eec52f4c9b49a5c61e0e8dd2fb0003368dc09d76dc7370844a24a439e3.

---

<a id="pubmed-pmid-35646620-enfuvirtide-v1"></a>

## Enfuvirtide biosynthesis in thermostable chaperone-based fusion.

> PubMed lists PMID 35646620 in Biotechnology reports (Amsterdam, Netherlands) as Journal Article, with publication-date metadata of 2022-05-14 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35646620-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35646620-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-35646620-enfuvirtide-v1
- Content SHA-256: `a136255e998df39e9f944319d2b9235504f416a008e2e3784c8d527adf9b765c`

### Claims and source pins

#### Headline

Enfuvirtide biosynthesis in thermostable chaperone-based fusion. ([`pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5`](#source-pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5))

#### Summary

PubMed lists PMID 35646620 in Biotechnology reports (Amsterdam, Netherlands) as Journal Article, with publication-date metadata of 2022-05-14 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5`](#source-pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5))

#### Paragraph 1

PubMed lists PMID 35646620 in Biotechnology reports (Amsterdam, Netherlands) as Journal Article, with publication-date metadata of 2022-05-14 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5`](#source-pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5`](#source-pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5))

### Sources

<a id="source-pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5"></a>
- **Enfuvirtide biosynthesis in thermostable chaperone-based fusion. · retained source version 1:2022-07-16:current:50ab0b147ee56137097cdee8d3f7611d1d9e18e0526a3c425ac5e1e2e5b30188** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35646620/) (`pubmed-observation-pmid-35646620-2022-07-16-50ab0b147ee5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enfuvirtide biosynthesis in thermostable chaperone-based fusion." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-35646620-enfuvirtide-v1 SHA-256: a136255e998df39e9f944319d2b9235504f416a008e2e3784c8d527adf9b765c.

---

<a id="pubmed-pmid-37120679-enfuvirtide-v1"></a>

## Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel.

> PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37120679-enfuvirtide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-07-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37120679-enfuvirtide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-37120679-enfuvirtide-v1
- Content SHA-256: `8a7cf60ac02c8d99e85cd45f96db346ec75e4a7e96e8e972be9412473a298c2f`

### Claims and source pins

#### Headline

Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel. ([`pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c`](#source-pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c))

#### Summary

PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c`](#source-pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c))

#### Paragraph 1

PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c`](#source-pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c`](#source-pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c))

### Sources

<a id="source-pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c"></a>
- **Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel. · retained source version 1:2023-07-05:current:1dd5ed51c40c6b28a075f63e025e9076801d7a846caccd3001fa8f05c85f6f12** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37120679/) (`pubmed-observation-pmid-37120679-2023-07-05-1dd5ed51c40c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/enfuvirtide.json#pubmed-pmid-37120679-enfuvirtide-v1 SHA-256: 8a7cf60ac02c8d99e85cd45f96db346ec75e4a7e96e8e972be9412473a298c2f.

